地拉罗司铁螯合治疗输血依赖的高危骨髓增生异常综合征:一项回顾性多中心研究
这项回顾性多中心研究纳入51例输血依赖的中危至极高危骨髓增生异常综合征(MDS)患者,口服地拉罗司(DFX)中位剂量1000 mg/日、中位疗程11个月,36例(71%)同时接受阿扎胞苷。中位铁蛋白从基线1709 μg/l降至治疗12个月后1100 μg/l(P=0.02),8例(16%)出现2-3级毒性。作者认为DFX在部分高危MDS患者中可行,但需更大规模前瞻性研究证实临床获益。
要点
- 51例输血依赖的中危至极高危MDS患者接受地拉罗司,36例(71%)联用阿扎胞苷。
- 中位铁蛋白由基线1709 μg/l降至12个月时1100 μg/l(P=0.02)。
- 8例(16%)出现2-3级肾或胃肠道毒性,其中4例(8%)需中断用药。
核心结论
- 作者认为地拉罗司在高危MDS中的安全性和疗效与低危MDS中观察到的结果相当,数据提示DFX可行并可能考虑用于经选择的高危MDS患者,但需更大规模前瞻性研究证实真实临床获益。
研究设计与样本
- 回顾性、多中心研究,纳入51例按修订版国际预后评分系统为中间至极高危、输血依赖的MDS患者,口服地拉罗司(DFX)治疗。
- 36例(71%)同时接受阿扎胞苷;DFX中位剂量1000 mg/日(范围375-2500 mg),中位治疗11个月(范围0.4-75个月)。
- 中位随访35.3个月。
主要发现
- 中位铁蛋白从基线1709 μg/l降至治疗12个月后1100 μg/l(P=0.02)。
- 8例(16%)出现2-3级毒性(肾脏或胃肠道),其中4例(8%)需中断用药。
- 基线转氨酶异常17例,DFX治疗下8例改善或恢复正常;1例出现显著血液学改善。
- 中位随访35.3个月时,中位总生存期为37.5个月。
临床怎么用
- 作者认为DFX可行,并可能考虑用于经选择的高危MDS患者;作者同时指出需更大规模前瞻性研究证实真实临床获益。
局限性
- 原文指出需要更大规模的前瞻性研究来证明真实的临床获益。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Iron chelation is controversial in higher risk myelodysplastic syndromes (HR-MDS), outside the allogeneic transplant setting. We conducted a retrospective, multicentre study in 51 patients with transfusion-dependent, intermediate-to-very high risk MDS, according to the revised international prognostic scoring system, treated with the oral iron chelating agent deferasirox (DFX). Thirty-six patients (71%) received azacitidine concomitantly. DFX was given at a median dose of 1000 mg/day (range 375-2500 mg) for a median of 11 months (range 0·4-75). Eight patients (16%) showed grade 2-3 toxicities (renal or gastrointestinal), 4 of whom (8%) required drug interruption. Median ferritin levels decreased from 1709 μg/l at baseline to 1100 μg/l after 12 months of treatment (P = 0·02). Seventeen patients showed abnormal transaminase levels at baseline, which improved or normalized under DFX treatment in eight cases. One patient showed a remarkable haematological improvement. At a median follow up of 35·3 months, median overall survival was 37·5 months. The results of this first survey of DFX in HR-MDS are comparable, in terms of safety and efficacy, with those observed in lower-risk MDS. Though larger, prospective studies are required to demonstrate real clinical benefits, our data suggest that DFX is feasible and might be considered in a selected cohort of HR-MDS patients.
引用
- Musto P, Maurillo L, Simeon V, et al. Iron-chelating therapy with deferasirox in transfusion-dependent, higher risk myelodysplastic syndromes: a retrospective, multicentre study. Br J Haematol. 2017. PMID: 28419408. doi:10.1111/bjh.14621
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。